Intravitreal Bevacizumab in the treatment of neovascular glaucoma secondary to central retinal vein occlusion: a case reportReportar como inadecuado




Intravitreal Bevacizumab in the treatment of neovascular glaucoma secondary to central retinal vein occlusion: a case report - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Cases Journal

, 2:176

First Online: 30 October 2009Received: 02 October 2009Accepted: 30 October 2009DOI: 10.1186-1757-1626-2-176

Cite this article as: Alasil, T. & Rauser, M.E. Cases Journal 2009 2: 176. doi:10.1186-1757-1626-2-176

Abstract

IntroductionEvery eye with central retinal vein occlusion CRVO is at risk for developing neovascular glaucoma NVG. Vascular endothelial growth factor VEGF has been shown to play a key role in the development of NVG in CRVO. Bevacizumab Avastin; Genentech, San Francisco, CA is a recombinant monoclonal antibody binding all isoforms of VEGF. Several studies have demonstrated intravitreal bevacizumab-induced regression of iris and angle neovascularisation associated with NVG.

Case presentationA 74 year old female presented with acute onset decreased vision in the right eye. Ophthalmic exam revealed acute non-ischemic CRVO in the right eye. A month later, follow up exam showed progression into ischemic CRVO and secondary NVG, which was successfully treated with intravitreal Bevacizumab followed by pan retinal photocoagulation PRP.

ConclusionOur case report highlights the use of intravitreal Bevacizumab in combination with PRP for the treatment of NVG secondary to CRVO.

Electronic supplementary materialThe online version of this article doi:10.1186-1757-1626-2-176 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Autor: Tarek Alasil - Michael E Rauser

Fuente: https://link.springer.com/







Documentos relacionados